MRNA weapon takes aim at hard-to-treat blood cancers
NCT ID NCT07362732
First seen Jan 24, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This early-phase study tests a new mRNA drug called WGb-0302 for people with blood cancers like multiple myeloma that have returned or stopped responding to standard treatments. The drug uses mRNA technology to help the body target a protein called BCMA found on cancer cells. About 20 participants will receive the injection to find the safest dose and see if it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.